If this message is not displayed correctly, click here.
NDT-Educational

NDT-Educational Newsletter                                                       Issue 22 - July 2020

EDITOR IN CHIEF: Davide Bolignano
EDITORIAL BOARD: click here for the complete list
NEWSLETTER DESIGN: Francesca Trebelli
Summary Reports from 57th ERA-EDTA Virtual Congress
Industry Symposia

Clinical Conundrums in aTypical HUS - Organised by ALEXION PHARMA GMBH
Alexion Is

Atypical hemolytic uremic syndrome (aHUS) is an extremely rare, complement-mediated disease characterized by acute kidney injury, thrombocytopenia, and microangiopathic hemolytic anemia that occurs with a reported annual incidence for all ages ranging from 0.23 to 1.9 million.

Read more
Alexion Is
Industry Symposium Webcast

View the webcast of this Industry Symposium on the 57th ERA-EDTA Congress Virtual Meeting

View the Webcast

K+: Recurrence, Restriction and Fluctuation - Organised by CHANGE IME in partnership with Leicester Diabetes Centre- Funded by an unrestricted educational grant from AstraZeneca

AstraZeneca HK IS

Hyperkalaemia (HK) is a potentially life-threatening condition with serious clinical and economic consequences. There is a U-shape relationship between serum potassium (K+) levels, mortality and major adverse cardiovascular events in patients with chronic kidney disease (CKD).

Read more
AstraZeneca HK Is
Industry Symposium Webcast

View the webcast of this Industry Symposium on the 57th ERA-EDTA Congress Virtual Meeting

View the Webcast

SGLT2 inhibition in CKD: Our chance to make a difference – Organised by CHANGE IME in partnership with Leicester Diabetes Centre, funded by an unrestricted educational grant from AstraZeneca

AstraZeneca SGLT2 IS

Chronic kidney disease (CKD) is highly prevalent worldwide, with up to 14% of people affected in some regions, and the number of potential or productive life years lost due to premature death or disability is rising, regardless of the underlying cause of renal damage (1, 2). It is estimated that 5 million individuals will require renal replacement therapy by 2030, presenting a substantial burden on health services worldwide.

Read more
AstraZeneca SGLT2 Is
Industry Symposium Webcast

View the webcast of this Industry Symposium on the 57th ERA-EDTA Congress Virtual Meeting

View the Webcast
Expert approaches to management across the CKD-MBD continuum - Organised by Vifor Fresenius Medical Care Renal Pharma Ltd.
Vifor CKD-MBD IS
The decline of kidney function in CKD patients is accompanied by progressive disruption of serum concentrations of phosphate and calcium, as well as changes in circulating levels of parathyroid hormone (PTH) and calcitriol, eventually leading to disorders of bone metabolism and vascular calcifications. The condition is termed chronic kidney disease-mineral and bone disorder (CKD-MBD) to describe the broader clinical syndrome encompassing mineral, bone, parathyroid, and cardiovascular abnormalities that develop as a complication of CKD.

 

Read more
Vifor CKD-MBD IS
Industry Symposium Webcast

View the webcast of this Industry Symposium on the 57th ERA-EDTA Congress Virtual Meeting

View the Webcast
FOLLOW US
Follow us Follow us Twitter Follow us LinkedinFollow us Instagram Follow us You Tube

The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the EU General Data Protection Regulation (2016/679). Unsubscribe